Hemostemix Inc.HEM.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · hemostemix.com

Hemostemix Inc. is a clinical-stage biotechnology company headquartered in Calgary, Canada, that develops blood-derived stem cell therapies. Its lead product, ACP-01, is in Phase II clinical trials for vascular diseases including peripheral arterial disease, angina pectoris, chronic limb threatening ischemia, and heart failure. The company also develops NCP-01, a preclinical product targeting neuropathic pain and motor function recovery.

Key ratios

ROA

-368.6%TTM

2025 -358.0%2024 -188.6%2023 -374.4%

Recent news

Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA 2026-08-20 · Newsfile Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell™ Longevity Clinical Trial 2026-08-12 · Newsfile Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026 2026-07-30 · Newsfile Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell's Excellent Results 2026-07-28 · Newsfile Hemostemix Grants Stock Options 2026-07-22 · Newsfile Hemostemix Closes $360,000 First Tranche of Private Placement 2026-06-26 · BioSpace Hemostemix' $1,000,000 Private Placement and Update 2026-06-18 · BioSpace Hemostemix Receives FDA Support for Its Basket Protocol Approach 2026-01-16 · Newsfile Corp

Track HEM.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer